Valeant Pharmaceuticals International (NYSE: VRX) is expected to report Q4 earnings on Feb. 28. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Valeant Pharmaceuticals International's revenues will grow 37.8% and EPS will grow 28.7%.

The average estimate for revenue is $948.4 million. On the bottom line, the average EPS estimate is $1.21.

Revenue details
 Last quarter, Valeant Pharmaceuticals International reported revenue of $884.1 million. GAAP reported sales were 47% higher than the prior-year quarter's $600.6 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, non-GAAP EPS came in at $1.15. GAAP EPS of $0.02 for Q3 were 85% lower than the prior-year quarter's $0.13 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 74.0%, 160 basis points better than the prior-year quarter. Operating margin was 25.8%, 170 basis points better than the prior-year quarter. Net margin was 0.9%, 590 basis points worse than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $3.50 billion. The average EPS estimate is $4.41.

Investor sentiment
 The stock has a three-star rating (out of five) at Motley Fool CAPS, with 194 members out of 219 rating the stock outperform, and 25 members rating it underperform. Among 74 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 67 give Valeant Pharmaceuticals International a green thumbs-up, and seven give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Valeant Pharmaceuticals International is outperform, with an average price target of $65.38.